argenx SE

ENXTBR:ARGX 株式レポート

時価総額：€45.5b

argenx 配当と自社株買い

配当金 基準チェック /06

argenx配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.5%

バイバック利回り

総株主利回り-0.5%
将来の配当利回り0.08%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

ナラティブ更新 • Jul 28

ARGX: Myositis Readouts And Forte Deal Will Drive Next Upside

Analysts have nudged their fair value estimate for argenx higher to about €906 from roughly €887, reflecting a slightly lower discount rate and marginally improved long term profitability assumptions, partly supported by a wave of price target increases after the Forte Biosciences acquisition and stronger Vyvgart performance in recent Q2 results. Analyst Commentary Recent research views on argenx cluster around two themes.
ナラティブ更新 • Jul 14

ARGX: Myositis Phase 3 Data Will Drive Next Leg Of Upside

The analyst price target for argenx has been raised by approximately €18 to reflect slightly higher modeled fair value and modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions, supported by recent Street research that highlights myositis as a key potential value driver for Vyvgart. Analyst Commentary Recent Street research on argenx continues to cluster around Vyvgart and its potential in myositis, with multiple firms updating valuation models and price targets.
ナラティブ更新 • Jun 30

ARGX: Myositis Phase 3 Readouts Will Shape Future Earnings Power

Analysts have nudged their average price targets for argenx higher, citing a series of recent target increases into the €1,059 to about €1,291 range and arguing that the market may still underappreciate the potential of Vyvgart in autoimmune myositis and related indications. Analyst Commentary Recent research on argenx centers on how Vyvgart and the broader myositis program could influence the company’s long term value, with several firms updating their models ahead of key Phase 3 readouts.
ナラティブ更新 • Jun 16

ARGX: Phase 3 Myositis And ALKIVIA Outcomes Will Test Elevated Stock Expectations

The analyst fair value estimate for argenx has been revised from €614.80 to €644.90 as analysts factor in higher Street price targets and upcoming Phase 3 myositis and ALKIVIA study readouts for Vyvgart and efgartigimod. Analyst Commentary on argenx Recent Street research around argenx highlights a mix of optimism on the clinical pipeline and caution on execution and valuation, giving investors a more balanced picture of risk around Vyvgart and efgartigimod ahead of the Phase 3 myositis and ALKIVIA readouts.
ナラティブ更新 • Jun 02

ARGX: Expanded gMG Label And Myositis Readouts Will Drive Future Repricing Potential

Analysts have nudged their blended price target for argenx higher to about €1,000, reflecting incremental target increases up to €1,291, as they point to upcoming Vyvgart and efgartigimod Phase 3 data and ongoing profitability as key supports for the updated view. Analyst Commentary Bullish analysts are leaning into a constructive view on argenx, pointing to upcoming clinical readouts and recent profitability as key pieces of the story rather than short term trading factors.
新しいナラティブ • May 20

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Investment Memo – argenx SE 1. Executive Summary argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases.
ナラティブ更新 • May 14

ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power

Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.
ナラティブ更新 • Apr 29

ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential

Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.
ナラティブ更新 • Apr 15

ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power

Analysts have made a modest upward tweak to the fair value estimate for argenx to €842.55, reflecting updated assumptions for Vyvgart momentum, slightly higher revenue growth expectations around 26.7%, a somewhat lower profit margin near 34.7%, and a higher future P/E of about 25.5x following recent price target revisions and ongoing support from research firms despite generally lower headline targets. Analyst Commentary Recent Street research on argenx reflects generally constructive views on Vyvgart execution and the broader pipeline, with some caution around spending plans and the current valuation.
ナラティブ更新 • Apr 01

ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential

Analysts have nudged the blended price target for argenx slightly higher to about €991. This reflects updated assumptions that pair more moderate revenue growth with a higher profit margin outlook and a somewhat richer future P/E, supported by recent research citing steady Vyvgart momentum, consistent profitability and a deep late stage pipeline.
ナラティブ更新 • Mar 17

ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside

Argenx's updated analyst price target reflects a modest recalibration, with fair value edging from about €845 to €839 as analysts factor in ongoing Vyvgart momentum, a slightly lower future P/E assumption and continued profitability. Analyst Commentary Recent Street research on argenx clusters around two themes: execution on Vyvgart and how much of that outlook is already reflected in the share price.
ナラティブ更新 • Mar 03

ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential

The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive.
ナラティブ更新 • Feb 17

ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside

Narrative Update Analysts have raised their average price target on argenx by a few euros to €825.51. This reflects updated models that incorporate slightly higher revenue growth assumptions, a modestly higher future P/E multiple and recent target increases from firms citing steady long term confidence in the story.
ナラティブ更新 • Feb 03

ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis

Analysts have lifted their fair value estimate for argenx from US$528.05 to US$614.80, citing updated models that incorporate revised revenue growth, profit margin and future P/E assumptions, in line with a series of recent price target increases from major brokerage firms. Analyst Commentary Recent Street research on argenx has featured a series of higher price targets in both U.S. dollars and euros, reflecting updated models rather than wholesale shifts in underlying views.
ナラティブ更新 • Jan 20

ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing

Analysts have raised their fair value estimate for argenx from about $885 to roughly $990.88, citing higher modeled revenue growth assumptions, updated P/E expectations, and a series of price target increases across the Street. Analysts continue to view the company constructively, even as some lists are being rebalanced.
ナラティブ更新 • Jan 06

ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks

Analysts have lifted their fair value estimate for argenx from $797.32 to $820.09. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E after recent research that highlighted solid Q3 execution, optimism around Vyvgart's opportunity and some recalibration of upside potential.
ナラティブ更新 • Dec 15

ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks

Analysts have nudged their average price target on argenx modestly higher by about $30 per share. This reflects stronger assumed revenue growth and higher future valuation multiples, even as they temper margin expectations in light of a more selective, probability-weighted view of the Vyvgart and empasiprubart pipelines.
ナラティブ更新 • Nov 30

ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations

Argenx's analyst price target has been modestly revised downward by approximately $4 to $766. Analysts are balancing optimism on new clinical data and pipeline expansion with tempered expectations following the recent stock rally.
ナラティブ更新 • Nov 16

ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm

Analysts have raised their price target for argenx by over $20 to approximately $770. They cite strong third-quarter performance, broadening growth drivers across Vyvgart indications, and confidence in the company’s expanding pipeline and commercial prospects.
ナラティブ更新 • Nov 02

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook

Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.
ナラティブ更新 • Sep 25

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

argenx’s consensus price target has been revised upward to €724.38 as analysts raise growth forecasts following strong Phase 3 Vyvgart data and expanding market opportunity, while improved revenue projections and robust pipeline momentum continue to offset valuation concerns. Analyst Commentary Bullish analysts are raising price targets on Argenx following positive topline Phase 3 data for Vyvgart in seronegative myasthenia gravis and successful primary endpoint achievement across patient subtypes, which expands the addressable market.
ナラティブ更新 • Aug 29

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

argenx’s price target has been raised to €705.90 as analysts cite strong Vyvgart Phase 3 results, raised U.S. sales expectations, visible pipeline catalysts, and resilient uptake despite recent safety concerns. Analyst Commentary Bullish analysts cite Vyvgart’s positive Phase 3 ADAPT SERON results in seronegative generalized myasthenia gravis (gMG), demonstrating clinical improvement and supporting expansion into new patient subtypes.
ナラティブ更新 • Aug 06

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31. What's in the News Argenx and Unnatural Products Inc.
User avatar
新しいナラティブ • Apr 27

Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach

Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues.

決済の安定と成長

配当データの取得

安定した配当: ARGXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: ARGXの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

argenx 配当利回り対市場
ARGX 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (ARGX)n/a
市場下位25% (BE)2.2%
市場トップ25% (BE)6.7%
業界平均 (Biotechs)2.3%
アナリスト予想 (ARGX) (最長3年)0.08%

注目すべき配当: ARGXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: ARGXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: ARGXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: ARGXが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/05 21:27
終値2026/08/05 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

argenx SE 29 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。52

アナリスト機関
null nullBaird
Colleen KusyBaird
Joel BeattyBaird